Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more
Bioventix (BVXP) - Total Assets
Latest total assets as of June 2025: GBX12.86 Million GBX
Based on the latest financial reports, Bioventix (BVXP) holds total assets worth GBX12.86 Million GBX as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioventix - Total Assets Trend (2006–2025)
This chart illustrates how Bioventix’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bioventix - Asset Composition Analysis
Current Asset Composition (June 2025)
Bioventix's total assets of GBX12.86 Million consist of 93.5% current assets and 6.5% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 39.5% |
| Accounts Receivable | GBX6.24 Million | 48.5% |
| Inventory | GBX689.40K | 5.4% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Bioventix's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioventix's current assets represent 93.5% of total assets in 2025, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 39.5% of total assets in 2025, up from 20.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 21.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 48.5% of total assets.
Bioventix Competitors by Total Assets
Key competitors of Bioventix based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Bioventix - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Bioventix generates 1.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Bioventix generates $ 58.96 in net profit.
Bioventix - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.17 | 7.42 | 16.43 |
| Quick Ratio | 8.65 | 7.07 | 16.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX10.72 Million | GBX 11.10 Million | GBX 11.24 Million |
Bioventix - Advanced Valuation Insights
This section examines the relationship between Bioventix's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.01 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.3% |
| Total Assets | GBX12.86 Million |
| Market Capitalization | $9.85K USD |
Valuation Analysis
Below Book Valuation: The market values Bioventix's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bioventix's assets decreased by 6.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bioventix (2006–2025)
The table below shows the annual total assets of Bioventix from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | GBX12.86 Million | -6.32% |
| 2024-06-30 | GBX13.73 Million | +3.38% |
| 2023-06-30 | GBX13.28 Million | +1.25% |
| 2022-06-30 | GBX13.12 Million | +1.63% |
| 2021-06-30 | GBX12.91 Million | -2.95% |
| 2020-06-30 | GBX13.30 Million | +14.52% |
| 2019-06-30 | GBX11.61 Million | -2.21% |
| 2018-06-30 | GBX11.88 Million | +14.40% |
| 2017-06-30 | GBX10.38 Million | +18.30% |
| 2016-06-30 | GBX8.78 Million | +27.14% |
| 2015-06-30 | GBX6.90 Million | +19.68% |
| 2014-06-30 | GBX5.77 Million | +27.81% |
| 2013-06-30 | GBX4.51 Million | +26.99% |
| 2012-06-30 | GBX3.55 Million | +23.89% |
| 2011-06-30 | GBX2.87 Million | +12.60% |
| 2010-06-30 | GBX2.55 Million | +7.06% |
| 2009-06-30 | GBX2.38 Million | +69.08% |
| 2008-06-30 | GBX1.41 Million | +46.56% |
| 2007-06-30 | GBX960.00K | -6.52% |
| 2006-06-30 | GBX1.03 Million | -- |